Autologous stem cell transplantation in myelodysplastic syndromes.

  title={Autologous stem cell transplantation in myelodysplastic syndromes.},
  author={Theo J M de Witte and Stefan Suciu and Ronald Brand and Petra Muus and Nicolaus Kr{\"o}ger},
  journal={Seminars in hematology},
  volume={44 4},
Allogeneic stem cell transplantation (SCT) is the treatment of choice for the majority of young patients with myelodysplasia (MDS) who have a histocompatible donor (sibling or unrelated donor). For some patients lacking a human leukocyte antigen (HLA)-compatible donor, chemotherapy followed by autologous SCT may be a reasonable alternative, especially for patients with therapy-related MDS/acute myeloid leukemia (AML). A substantial number of candidates may not be eligible for autologous SCT due… CONTINUE READING